Risk Factors for Death in Patients with Atrial Fibrillation

  • Xinrui Chen The First Affiliated Hospital of Chongqing Medical University Geriatrics
  • Gang Li The First Affiliated Hospital of Chongqing Medical University Geriatrics
  • Yufeng Li The First Affiliated Hospital of Chongqing Medical University Geriatrics
  • Linping Wei The First Affiliated Hospital of Chongqing Medical University Geriatrics
Keywords: Atrial Fibrillation; Death; Risk Factors


With the aging society and increasing risk factors for cardiovascular diseases, the incidence of atrial fbrillation is gradually in-creasing, seriously afecting human health. Previous studies have shown that hypertension, diabetes, heart failure, chronic kidney disease, etc, increase the risk of death of patients with atrial fbrillation. Research has shown that cardiac pathological remodeling is the fundamental pathophysiological mechanism for atrial fbrillation, which is closely related to thromboembolism and death in patients with atrial fbrillation. At present, there is limited research on the risk factors for increased mortality in patients with atrial fbrillation. Therefore, this article will review the related factors that increase the risk of death in patients with atrial fbrillation.


[1] Benjamin EJ, Wolf PA, D’Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circu_x005flation 1998; 98(10):946-952.

[2] Antikainen RL, Peters R, Beckett NS, et al. Atrial fibrillation and the risk of cardiovascular disease and mortality in the Hypertension in the Very Elderly Trial. J Hypertens 2020; 38(5):839-844.

[3] Andrade J, Khairy P, Dobrev D, et al. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical

features, epidemiology, and mechanisms. Circ Res 2014; 114(9):1453-1468.

[4] Staerk L, Sherer JA, Ko D, et al. Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes. Circ Res 2017;


[5] Kamel H, Okin PM, Elkind MS, et al. Atrial Fibrillation and Mechanisms of Stroke: Time for a New Model. Stroke 2016;


[6] Vinding NE, Kristensen SL, Rorth R, et al. Ischemic Stroke Severity and Mortality in Patients With and Without Atrial Fibrillation.

J Am Heart Assoc 2022; 11(4): e022638.

[7] Gomez-Outes A, Suarez-Gea ML, Garcia-Pinilla JM. Causes of death in atrial fibrillation: Challenges and opportunities. Trends

Cardiovasc Med 2017; 27(7):494-503.

[8] Sairenchi T, Yamagishi K, Iso H, et al. Atrial Fibrillation With and Without Cardiovascular Risk Factors and Stroke Mortality. J

Atheroscler Thromb 2021; 28(3):241-248.

[9] Proietti M, Laroche C, Nieuwlaat R, et al. Increased burden of comorbidities and risk of cardiovascular death in atrial fibrillation

patients in Europe over ten years: A comparison between EORP-AF pilot and EHS-AF registries. Eur J Intern Med 2018; 55:28-34.

[10] Xia Z, Dang W, Jiang Y, et al. Association Between Atrial Fibrillation and the Risk of Cardiovascular Mortality Among Elderly

Adults With Ischemic Stroke in Northeast China: A Community-Based Prospective Study. Front Aging Neurosci 2022; 14:836425.

[11] Waldmann V, Jouven X, Narayanan K, et al. Association Between Atrial Fibrillation and Sudden Cardiac Death: Pathophysiological and Epidemiological Insights. Circ Res 2020; 127(2):301-309.

[12] Poli D, Antonucci E. Epidemiology, diagnosis, and management of atrial fibrillation in women. Int J Womens Health 2015; 7:605-


[13] Roquer J, Rodriguez-Campello A, Gomis M, et al. Comparison of the impact of atrial fibrillation on the risk of early death after

stroke in women versus men. J Neurol 2006; 253(11):1484-1489.

[14] Emdin CA, Wong CX, Hsiao AJ, et al. Atrial fibrillation as risk factor for cardiovascular disease and death in women compared

with men: systematic review and meta-analysis of cohort studies. BMJ 2016; 532:h7013.

[15] Humphries KH, Kerr CR, Connolly SJ, et al. New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome.

Circulation 2001; 103(19):2365-2370.

[16] Roden DM, Kannankeril P, Darbar D. On the relationship among QT interval, atrial fibrillation, and torsade de pointes. Europace

2007; 9 Suppl 4(Suppl 4):iv1-3.

[17] Albertsen IE, Rasmussen LH, Lane DA, et al. The impact of smoking on thromboembolism and mortality in patients with incident

atrial fibrillation: insights from the Danish Diet, Cancer, and Health study. Chest 2014; 145(3):559-566.

[18] Kwon Y, Norby FL, Jensen PN, et al. Association of Smoking, Alcohol, and Obesity with Cardiovascular Death and Ischemic

Stroke in Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study and Cardiovascular Health Study (CHS). PLoS One

2016; 11(1):e0147065.

[19] Lee SR, Choi EK, Jung JH, et al. Smoking Cessation after Diagnosis of New-Onset Atrial Fibrillation and the Risk of Stroke and Death. J Clin Med 2021; 10(11).

[20] Chamberlain AM, Alonso A, Gersh BJ, et al. Multimorbidity and the risk of hospitalization and death in atrial fibrillation: A population-based study. Am Heart J 2017; 185:74-84.

[21] Huxley RR, Lopez FL, Folsom AR, et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline

risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2011; 123(14):1501-1508.

[22] Wong CX, Ganesan AN, Selvanayagam JB. Epicardial fat and atrial fibrillation: current evidence, potential mechanisms, clinical

implications, and future directions. Eur Heart J 2017; 38(17):1294-1302.

[23] Homan EA, Reyes MV, Hickey KT, et al. Clinical Overview of Obesity and Diabetes Mellitus as Risk Factors for Atrial Fibrillation and Sudden Cardiac Death. Front Physiol 2018; 9:1847.

[24] Dai H, Zhang Q, Much AA, et al. Global, regional, and national prevalence, incidence, mortality, and risk factors for atrial fibrillation, 1990-2017: results from the Global Burden of Disease Study 2017. Eur Heart J Qual Care Clin Outcomes 2021; 7(6):574-582.

[25] Wang L, Du X, Dong JZ, et al. Body mass index and all-cause mortality in patients with atrial fibrillation: insights from the China

atrial fibrillation registry study. Clin Res Cardiol 2019; 108(12):1371-1380.

[26] Yang D, Ye S, Zhang K, et al. Association between obesity and short- and medium-term mortality in critically ill patients with atrial fibrillation: a retrospective cohort study. BMC Cardiovasc Disord 2023; 23(1):150.

[27] Zhou X, Dudley SC, Jr. Evidence for Inflammation as a Driver of Atrial Fibrillation. Front Cardiovasc Med 2020; 7:62.

[28] Aulin J, Hijazi Z, Siegbahn A, et al. Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial

fibrillation: Insights from ARISTOTLE and RE-LY trials. J Thromb Haemost 2020; 18(9):2287-2295.

[29] Hermida J, Lopez FL, Montes R, et al. Usefulness of high-sensitivity C-reactive protein to predict mortality in patients with atrial

fibrillation (from the Atherosclerosis Risk In Communities [ARIC] Study). Am J Cardiol 2012; 109(1):95-99.

[30] Sulzgruber P, Koller L, Winter MP, et al. The impact of CD4(+)CD28(null) T-lymphocytes on atrial fibrillation and mortality in

patients with chronic heart failure. Thromb Haemost 2017; 117(2):349-356.

[31] Hu YF, Chen YJ, Lin YJ, et al. Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol 2015; 12(4):230-243.

[32] Lip GY, Patel JV, Hughes E, et al. High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and

platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and

prognosis. Stroke 2007; 38(4):1229-1237.

[33] Aune D, Mahamat-Saleh Y, Kobeissi E, et al. Blood pressure, hypertension and the risk of atrial fibrillation: a systematic review

and meta-analysis of cohort studies. Eur J Epidemiol 2023; 38(2):145-178.

[34] JanPing Wang, QiQiang Jie, Chang Pan. The effect of hypertension on short-term hospital mortality in patients with non valvular

atrial fibrillation after anticoagulation therapy. Journal of Clinical Military Medicine2021; (12):1337-1339.

[35] Dan GA, Badila E, Weiss E, et al. Arterial hypertension in patients with atrial fibrillation in Europe: A report from the EURObservational Research Programme pilot survey on atrial fibrillation. Int J Cardiol 2018; 254:136-141.

[36] Bansal N, Xie D, Sha D, et al. Cardiovascular Events after New-Onset Atrial Fibrillation in Adults with CKD: Results from the

Chronic Renal Insufficiency Cohort (CRIC) Study. J Am Soc Nephrol 2018; 29(12):2859-2869.

[37] Ru Wang, JunLu Zhang, AiJun Xing,et al. The effect of chronic renal dysfunction on cardiovascular and cerebrovascular death in

patients with atrial fibrillation. Chinese Journal of Cardiac Pacing and Electrophysiology 2016; (03):242-245.

[38] Liampas E, Kartas A, Samaras A, et al. Renal function and mortality in patients with atrial fibrillation. J Cardiovasc Med (Hagerstown) 2022; 23(7):430-438.

[39] Chen SC, Su HM, Hung CC, et al. Echocardiographic parameters are independently associated with rate of renal function decline

and progression to dialysis in patients with chronic kidney disease. Clin J Am Soc Nephrol 2011; 6(12):2750-2758.

[40] Burstein B, Qi XY, Yeh YH, C et al. Atrial cardiomyocyte tachycardia alters cardiac fibroblast function: a novel consideration in

atrial remodeling. Cardiovasc Res 2007; 76(3):442-452.

[41] Polovina M, Lund LH, Dikic D, et al. Type 2 diabetes increases the long-term risk of heart failure and mortality in patients with

atrial fibrillation. Eur J Heart Fail 2020; 22(1):113-125.

[42] Karayiannides S, Lundman P, Friberg L, et al. High overall cardiovascular risk and mortality in patients with atrial fibrillation and

diabetes: A nationwide report. Diab Vasc Dis Res 2018; 15(1):31-38.

[43] Xu J, Sun Y, Gong D, et al. Impact of preexisting diabetes mellitus on cardiovascular and all-cause mortality in patients with atrial

fibrillation: A meta-analysis. Front Endocrinol (Lausanne) 2022; 13:921159.

[44] Goudis CA, Korantzopoulos P, Ntalas IV, et al. Diabetes mellitus and atrial fibrillation: Pathophysiological mechanisms and potential upstream therapies. Int J Cardiol 2015; 184:617-622.

[45] Marijon E, Le Heuzey JY, Connolly S, et al. Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation 2013; 128(20):2192-2201.

[46] Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence

on mortality: the Framingham Heart Study. Circulation 2003; 107(23):2920-2925.

[47] Healey JS, Oldgren J, Ezekowitz M, et al. Occurrence of death and stroke in patients in 47 countries 1 year after presenting with

atrial fibrillation: a cohort study. Lancet 2016; 388(10050):1161-1169.

[48] Packer M. Neurohormonal Antagonists Are Preferred to an Implantable Cardioverter-Defibrillator in Preventing Sudden Death in

Heart Failure. JACC Heart Fail 2019; 7(10):902-906.

[49] Triposkiadis F, Giamouzis G, Parissis J, Set al. Reframing the association and significance of co-morbidities in heart failure. Eur J

Heart Fail 2016; 18(7):744-758.

Review Article